FDA Approves OZURDEX — Allergan, Inc.

Allergan, Inc. secured FDA approval for its intravitreal dexamethasone implant OZURDEX on June 17, a move that solidified the company's leadership position in the anti-inflammatory ophthalmology market while establishing a pivotal long-term treatment option.